JP2019512495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512495A5 JP2019512495A5 JP2018548236A JP2018548236A JP2019512495A5 JP 2019512495 A5 JP2019512495 A5 JP 2019512495A5 JP 2018548236 A JP2018548236 A JP 2018548236A JP 2018548236 A JP2018548236 A JP 2018548236A JP 2019512495 A5 JP2019512495 A5 JP 2019512495A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- salt
- methylpiperazin
- pyran
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 9
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 8
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 8
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- -1 tetrahydro-2H-pyran-4-ylamino Chemical group 0.000 claims 2
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314700P | 2016-03-29 | 2016-03-29 | |
| US62/314700 | 2016-03-29 | ||
| US201662368343P | 2016-07-29 | 2016-07-29 | |
| US62/368343 | 2016-07-29 | ||
| PCT/JP2017/012293 WO2017170348A1 (en) | 2016-03-29 | 2017-03-27 | Combination therapy for the treatment of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512495A JP2019512495A (ja) | 2019-05-16 |
| JP2019512495A5 true JP2019512495A5 (cg-RX-API-DMAC7.html) | 2020-04-09 |
Family
ID=59965623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548236A Pending JP2019512495A (ja) | 2016-03-29 | 2017-03-27 | 急性骨髄性白血病の治療のための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190117649A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3436014A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019512495A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180124055A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108883109A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018069111A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3018155A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018011975A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018134167A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017170348A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| CN113490497B (zh) * | 2019-02-22 | 2025-04-04 | 韩美药品株式会社 | 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物 |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| JP7577672B2 (ja) * | 2019-02-22 | 2024-11-05 | ハンミ ファーマシューティカルズ カンパニー リミテッド | Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物 |
| MY204603A (en) | 2019-04-03 | 2024-09-05 | Astellas Pharma Inc | Pharmaceutical composition |
| AU2020308814A1 (en) | 2019-06-27 | 2022-02-03 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents |
| US20230029336A1 (en) * | 2019-10-14 | 2023-01-26 | Astrazeneca Ab | Combination Therapy for Treating a Hematological Malignancy |
| US20220387362A1 (en) * | 2019-10-21 | 2022-12-08 | Rhizen Pharmaceuticals Ag | Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| KR102559124B1 (ko) | 2022-08-25 | 2023-07-26 | 주식회사 엔젠바이오 | Flt3 유전자 증폭용 조성물 및 이의 용도 |
-
2017
- 2017-03-27 WO PCT/JP2017/012293 patent/WO2017170348A1/en not_active Ceased
- 2017-03-27 JP JP2018548236A patent/JP2019512495A/ja active Pending
- 2017-03-27 MX MX2018011975A patent/MX2018011975A/es unknown
- 2017-03-27 BR BR112018069111-9A patent/BR112018069111A2/pt not_active Application Discontinuation
- 2017-03-27 RU RU2018134167A patent/RU2018134167A/ru not_active Application Discontinuation
- 2017-03-27 US US16/089,603 patent/US20190117649A1/en not_active Abandoned
- 2017-03-27 EP EP17774885.2A patent/EP3436014A4/en not_active Withdrawn
- 2017-03-27 CA CA3018155A patent/CA3018155A1/en not_active Abandoned
- 2017-03-27 KR KR1020187028124A patent/KR20180124055A/ko not_active Withdrawn
- 2017-03-27 CN CN201780021735.4A patent/CN108883109A/zh active Pending
-
2020
- 2020-07-30 US US16/943,379 patent/US20200360372A1/en not_active Abandoned